Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. - Wikidata - awgldk - TriplyDB

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

http://www.wikidata.org/entity/Q40589724

about

Japanese encephalitis-a pathological and clinical perspective Vaccines for preventing Japanese encephalitis The yellow fever 17D virus as a platform for new live attenuated vaccines Japanese encephalitis: the virus and vaccines Vaccine-mediated immunity against dengue and the potential for long-term protection against disease Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse Model An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice Production of Pseudoinfectious Yellow Fever Virus with a Two-Component Genome Production and characterization of vaccines based on flaviviruses defective in replication Live Chimeric and Inactivated Japanese Encephalitis Virus Vaccines Differ in Their Cross-Protective Values against Murray Valley Encephalitis Virus Evaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization Tests Wanted, dead or alive: New viral vaccines Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses Vaccination strategies against Zika virus Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization How advances in immunology provide insight into improving vaccine efficacy.Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.History of vaccination New Japanese encephalitis vaccines: alternatives to production in mouse brain.Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Yellow fever: the recurring plague.ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.Japanese Encephalitis Vaccines Prevention of yellow fever in persons traveling to the tropics.Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.Japanese encephalitis vaccine in travelers.Current trends in West Nile virus vaccine development.Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review Recent advancement in flavivirus vaccine development.A chimeric live attenuated vaccine against Japanese encephalitis.Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic.Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis Yellow fever vaccine.Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment

P2860

Q21144539-479EBBA2-E986-42FA-BE3E-27F94DF4726E Q24243819-5E930C74-3C6D-4430-A013-D0DE9D316D9B Q26865102-A28E8304-491D-4167-89BA-F0B67C65AD65 Q27010434-8950C3C2-76F2-4326-B2C6-ECEF02B2E953 Q27014663-419D7DD8-1961-4041-8E0F-4637C1294B33 Q27473317-A4CF9C5C-221F-4C80-856C-7E999EEB456C Q27481478-C920A2E6-FB08-48C9-A4A5-D292394CAE0E Q27481832-42287385-6D5E-4EC2-8091-A5A91D539CA9 Q27484992-60615C10-AC18-438D-9B78-B0166CD41E43 Q27486374-305D5608-75E2-463B-8BCA-E1B8E5BE2775 Q27487967-0592B6DF-C245-45C9-B0C5-51CE2BAA633D Q27488878-F5BD2C2D-1172-4E46-9360-42A01C339449 Q27489979-2BEC6D87-C61D-4C85-8DB2-9911BE6D12E7 Q27860800-9C8264DB-02F0-4BD9-A0A5-BB292D2582C8 Q29571224-71A0A04B-FE11-4491-B852-E91E8DBE5009 Q33712740-44B4EB2B-884F-4665-8589-376B957A7641 Q33896995-65E7B36B-2982-45C4-AFC4-8DD42BF685DB Q33992835-54BEAE32-7934-43AC-ACA0-5E2C6E00C80D Q34119899-AAE2B521-4800-4AD6-9D3A-1923F10E06DB Q34173039-D3A2CC97-572A-4960-9E5C-A53D3BBB9AA5 Q34258885-6D0CDAF6-08F9-4E6B-8250-FD670BF2A56B Q34359311-83314D67-428B-4CBC-ABC2-CC96A8218A12 Q34362322-ED4EACA5-DC56-4092-93AC-8EEE28E7B348 Q34466587-63F20A0C-8C50-421B-9145-E10FE63398FB Q34618456-51E07B9E-FD75-419B-9439-9045DD9DF891 Q34694948-B0C7BEBF-5292-4EA4-AF9B-53676C2E5D7A Q34694967-F2B19257-13B0-4417-836E-319D011DF404 Q34770828-1E77AD99-D154-4D08-BD6A-A16CA408A59C Q34787426-5032BBEF-F839-43CF-B372-F9850587C180 Q34788758-D56D3E60-9672-40D4-9AF9-646239E8FBFA Q35127585-661B5039-CF6B-4D9B-8531-336C5516C841 Q35246126-CE9EC9FD-EEA7-4E1B-B475-1D50F93DB143 Q35558900-5FCF8A25-EBD7-478A-9EF0-8D5ED6557B44 Q35728621-F5E3E64F-162E-4B86-B6DD-DF22FDDA79F0 Q35791746-1D543A47-540D-41F5-AB3D-657D79948A40 Q35802862-024BEF1E-98CF-4846-979E-51AF6EB2C5E9 Q35814043-F9E61352-0F11-497E-80EA-F6F00CB76E78 Q36082908-C2CC5A01-EB3E-4C6E-B325-D50DD0BC4A4D Q36238729-267EF96A-A13E-4B51-8078-4FE6DE0AD9AD Q36307457-9218AEEB-3B4E-454B-BAE9-40CED40246C6

P2860

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

http://www.wikidata.org/entity/Q40589724

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Clinical proof of principle fo ...... against flavivirus infections.

@en

type

label

Clinical proof of principle fo ...... against flavivirus infections.

@en

prefLabel

Clinical proof of principle fo ...... against flavivirus infections.

@en

P1433

Q40589724-262FDC22-3B65-453A-9491-DCA71A8BA45A

P1476

Q40589724-FAB6ACB7-4DFD-4B44-A5E5-7B5DCE0C0C5F

P2093

Q40589724-0F39C4F9-5BB6-4376-9C21-A2535EE61B62

Q40589724-1E14C264-4272-473D-8A0A-10A953C93D9E

Q40589724-3DF2F5C1-B718-4519-A952-DAD90D4CD115

Q40589724-65176353-8494-4DA6-A758-78F8C8357AFC

Q40589724-CCE17CFD-67AC-4D44-824F-320883E608C7

Q40589724-D32BA813-546E-460C-8794-58BD9CB561E7

Q40589724-D8A8C91F-4398-44BF-A2FC-7CB54E0B807E

Q40589724-EB062D8B-AAF4-43A3-A2D3-920553562576

Q40589724-ECA3B209-E589-465C-AC05-1BFB29192483

P304

Q40589724-E18FD599-D4C8-4DA2-A330-31CE1F86F8E8

P31

Q40589724-79F87824-6B5A-4272-B6C7-552952BA3DD5

P356

Q40589724-4E142B5C-51CF-4874-B7FF-148C3B7D0BDE

P407

Q40589724-672FE0B0-CF8D-44CE-8931-1BD31E870535

P433

Q40589724-1C236F23-6C14-4BA5-B6F9-DBA05BA01394

P478

Q40589724-7DF0CC6E-0081-4BF4-8CF0-5AF23A502EB3

P50

Q40589724-4E808B3B-A46C-4DA9-96CB-601886222805

Q40589724-6921D5A3-E6E7-4D39-A1F4-6F2A2A3FB239

P577

Q40589724-84B4460C-FFB3-49A4-89E0-0199D671E751

P698

Q40589724-719B4679-763A-4235-9FDE-E7F6AFE78796

P921

Q40589724-AA6D5318-27B4-4B61-BDF7-4DD45EBDA507

P356

S0264-410X(01)00457-1

P1433

P1476

Clinical proof of principle fo ...... against flavivirus infections.

@en

P2093

Casey T Johnson

http://www.w3.org/2001/XMLSchema#string

Juan Arroyo

http://www.w3.org/2001/XMLSchema#string

Karen McCarthy

http://www.w3.org/2001/XMLSchema#string

Keith H Wells

http://www.w3.org/2001/XMLSchema#string

Michael Knauber

http://www.w3.org/2001/XMLSchema#string

Philip Bedford

http://www.w3.org/2001/XMLSchema#string

Richard Nichols

http://www.w3.org/2001/XMLSchema#string

Ron Marchesani

http://www.w3.org/2001/XMLSchema#string

Sutee Yoksan

http://www.w3.org/2001/XMLSchema#string

P304

1004-1018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0264-410X(01)00457-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

7-8

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Thomas P. Monath

Farshad Guirakhoo

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11803060

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine